Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Addex to Present at the Swiss Equities Baader Conference

Addex to Present at Biotech Showcase™ 2024

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Addex Creates Treasury Shares

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Addex Convenes Extraordinary General Meeting

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance